We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Guillermo Argilés

Guillermo Argilés MD

Visiting Investigator, Luis Diaz Laboratory, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, New York

Dr Guillem Argilés is a physician scientist specialized in colorectal cancer (CRC). After obtaining his medical degree and medical oncology board certification in 2011, he was appointed as attending physician at the GI Malignancies Division at Vall d’Hebron University under the supervision of Josep Tabernero MD. PhD. During his 10 years of post-training clinical practice in that institution, Dr Argilés´ work have been focused on improving the standard of care, and developing new therapies for CRC patients, achieving a successful international career.  

Dr Argilés is the first author of the current edition of the European Guidelines for localized colon cancer, and author of 149 publications on drug development in CRC with a H-Index of 23.  He is a member of the CRC scientific Committee of the European Society for Medical Oncology and a regular speaker at international scientific meetings, Dr Argilés was the appointed discussant for the CRC Oral Abstract Session at the ASCO 2021 Annual Meeting and faculty of the CRC track in ESMO 2022.

During the last three years working in the Sloan Kettering Institute at Luis Diaz laboratory, Dr Argilés has been conducting several research projects centered in the development of new therapeutic strategies for CRC with high potential applicability and have contributed to several important publications for the institution like the dostarlimab study in neoadjuvant rectal MSI patients published in NEJM. 


Guillem Ariglés serves as a compensated medical advisor for Gadeta B.V.